Proteins for use in diagnosing and treating infection and disease

(canceled)

10-13. (canceled)

16-17. (canceled)

A method of treatment for HIV infection comprising administering to a human infected with HIV or at risk of HIV infection a composition comprising a thymus derived peptide and a pharmaceutically acceptable carrier, wherein the composition does not include every peptide of a thymus nuclear protein extract.

24-28. (canceled)

30-34. (canceled)

36-40. (canceled)

A kit comprising

• (a) a container housing a thymus derived peptide wherein the thymus derived peptide is a peptide of any of SEQ ID NO. 1-SEQ ID NO. 265;
• and
• (b) instructions for identifying a complex that is indicative of HIV-I infection.

A method of treatment for disease associated with a decrease in the number of TH cells comprising administering to a subject in need thereof a composition comprising a thymus derived peptide and a pharmaceutically acceptable carrier, wherein the composition is not a thymus nuclear protein extract, in an effective amount to treat the disease.

45-47. (canceled)

A method for treating cancer, comprising:

• administering to a subject having cancer a composition comprising a thymus derived peptide and a pharmaceutically acceptable carrier, wherein the composition is not a thymus nuclear protein extract, in an effective amount to treat the cancer in the subject.

49-52. (canceled)

A method for treating a viral infection, comprising:

• administering to a subject having or at risk of having a viral infection a composition comprising a thymus derived peptide and a pharmaceutically acceptable carrier, wherein the composition is not a thymus nuclear protein extract, in an effective amount to treat the viral infection in the subject.

54-59. (canceled)

A method for treating a subject having a cell or tissue graft, comprising:

• administering to the subject in need thereof composition comprising a thymus derived peptide and a pharmaceutically acceptable carrier, wherein the composition is not a thymus nuclear protein extract, in an effective amount to inhibit cell or tissue graft rejection in the subject.

62-63. (canceled)

A peptide having a peptide sequence corresponding to any one of SEQ ID NOs. 1-265.